Biogen Idec says that new data shows that an experimental therapy for MS--BG-12--prevented the worsening of brain lesions. In the trial, the drug reduced the conversion of inflammation spots into permanent damage--a key objective. The company is trying to get the first approval for an oral therapy for MS. Late-stage trials began in January. Report